What's it Worth? A Journal Club Podcast

Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and P4 Garrison Avery, as we discuss the RENAL-AF trial comparing apixaban vs warfarin in hemodialysis patients.  These authors aimed to assess safety and efficacy in one of the first prospective trials comparing DOACs with warfarin in hemodialysis patients. Ever read a trial that didn't enroll their goal number of patients? Le...

Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and Garrison Avery, student PharmD, as we evaluate the 52 week reported outcomes of the ongoing Resmetirom Phase 3 trial. This trial is our first look at a medication currently seeking FDA approval to halt and reverse NASH and liver fibrosis. We also discuss Bonferroni statistical analysis, patients excluded from the trial, and...

Did you miss us? We're back for Season 2 of What's it Worth! Join your host, Dr. Diana Langworthy, and co-host Garrison (Griest) Avery (back at the end of his APPE year for some more EBP fun!), as they find out if phenobarbital is beating benzos in severe alcohol withdrawal!  CI-WAt all the fuss is about in season two as we PAWSS and reflect on where single-site retrospective results and clinical...

Welcome to  What's it Worth - BONUS episode #2! Join your host Dr. Diana Langworthy and a come-back by P4 student co-host Marina Fahim as we get biosimilar! Our expert guest for this episode is Dr. Hannah Berg, Formulary Management Pharmacist at United Healthcare. We're discussing a trial that aimed to determine whether pegfilgrastim biosimilars were considered statistically equivalent to the pegf...

Welcome to  What's it Worth - a BONUS episode! Join your host Dr. Diana Langworthy and a come-back by P4 student co-host Garrison Griest as we get the scoop on poop! Our expert guest for this episode is Dr. Jen Ross, Antimicrobial Stewardship Clinical Pharmacist at M Health Fairview East and West Bank Hospitals. We're discussing a trial that evaluated the efficacy of a new orally administered feca...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy as we co-mingle with co-primary clues! Our expert guest for this episode is  Dr. Natalie Heinrich, Medication Therapy Management Clinical Pharmacist in Neurology at M Health Fairview. We're discussing a trial evaluated the efficacy of zavegepant, a novel CGRP antagonist for nasal administration, for the treatment of acute migraine at...

Welcome to  What's it Worth! Join your host Dr. Diana Langworthy, & co-host Marina Fahim, as we ATTACK the critique of a non-inferiotiy study design. Our expert guest for this episode is Dr. Betsy Hirsch, Assoiate Professor and Infectious Diseases Translational Researcher. We're discussing a trial that compared a new beta-lactam antibiotic, sulbactam/durlobactam, with colistin for the treatment of...

Welcome to  What's it Worth! Join your host, Dr. Diana Langworthy and co-host  Chelsea Bolier, PharmD, as we break down Delphi and learn more about analyzing qualitatitve data.  We're joined this month by  Dr. Joel Farley, PhD and Dr. Pamela Phelps, PharmD, FASHP -  two experts in the arena of determining the impact of clinical pharmacy services.    Key Points Determining the impact of clinical ph...

Welcome to  What's it Worth! Join your hosts, Dr. Diana Langworthy & Garrison Griest as we go retro to tackle confounding variables! We'll be reviewing an article that aimed to determine the risk of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis who are using proton pump inhibitors (PPIs).   Key Points Retrospective studies produce more opportunities for confounding variables t...

08Welcome to What's it Worth! Join your hosts, Dr. Diana Langworthy, Nathan Uk, and Garrison Griest as we walk you through composite outcomes with the CLEAR trial - a comparison of bempedoic acid versus placebo for preventing major adverse cardiovascular events (MACE) in patients who cannot tolerate statin therapy. We're joined by  Dr. Chrystian Pereira ,  PharmD, BCACP,  an ambulatory care pharma...

Welcome to What's it Worth! Join your hosts, Dr. Diana Langworthy, Nathan Uk, and Garrison Griest as we take on the evidence behind a trending treatment for COVID-19.  Our guest, Dr. Ann Philbrick, PharmD, BCACP, will share her expertise with medical cannabis products to help figure out what is TBD about CBD in COVID-19.     Key Points Cannabidiol (CBD) has some purported anti-inflammatory propert...

Welcome to What's it Worth! Join your host, Dr. Diana Langworthy as we're strengthening our EBP skills in power and subject allocation with the STRONG-HF trial - a prospective, randomized, open-label study comparing high-intensity titration to guideline-directed medical therapy vs usual cares in patients with recent heart failure exacerbations.  Special guest - Dr. Christian Bell, PharmD and PGY1...

Welcome to What's it Worth! Join Dr. Diana Langworthy, Garrison Griest, and Nathan Uk for our first episode where we go down the WATERFALL and take a deep dive into the details of a prospective, open-label trial comparing aggressive and moderate fluid resuscitation strategies in the initial treatment of acute pancreatitis. Key Points Aggressive fluid resuscitation has historically been preferred i...

BONUS EPISODE! We're dropping Episode 2 early so you have even more journal critique music to your ears. Welcome back to What's it Worth! Today we soar through the topics of pilot studies, medical cannabis, and cancer related pain. We are joined by Dr. Kirollos Hanna, Director of Pharmacy at Minnesota Oncology, as we attempt to take the pain out of assessing feasibility trials.   Key Points Pilot...